跳至主要内容
临床试验/IRCT20211102052944N2
IRCT20211102052944N2尚未招募2 期

Safety and efficacy evaluation of intra-articular knee transplantation of three consecutive doses of Platelet-Rich Plasma in patients with knee osteoarthritis: Interventional clinical trial, Phase II

Royan Stem Cell Technology Company0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
45 years 至 70 years(—)
性别
All

入选标准

  • 45-70 years
  • Kellgren and Lawrence grade of both knees between 2 and 3
  • knee pain for at least 4 months that has not responded to common medical and physical therapies.
  • Visual analogue score = 4
  • Informed consent

排除标准

  • Pregnancy or lactation
  • Presence of any concomitant knee injury that causes pain or swelling (eg, ligament damage or meniscal tear)
  • Intra-articular injection of hyalgan or steroid drugs during the last 2 months
  • Malalignment of the knee joint more than 15 degrees (diagnosis with triple joint view radiography)
  • Documented uncontrolled underlying diseases (including diabetes (HbA1c = 8), heart failure (EF<45%), kidney failure (Cr>2), liver failure (AST, ALT>100)
  • The existence of blood or cardiovascular diseases, infections and weak immunity, neoplasm, etc., which interfere with the evaluations.
  • History of orthopedic surgery in the spine or lower limbs
  • osteoarthritis of the hip or ankle joint
  • Known allergy to hyaluronic acid products
  • Taking aspirin one week before cell injection
  • History of coagulopathy or use of anticoagulant drugs

研究者

发起方
Royan Stem Cell Technology Company

相似试验

Effect of PRP derived from umbilical cord blood in... | 临床试验